Los Angeles Capital Management LLC Sells 13,960 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Los Angeles Capital Management LLC trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 14.7% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 80,862 shares of the biopharmaceutical company's stock after selling 13,960 shares during the quarter. Los Angeles Capital Management LLC owned about 0.06% of Alnylam Pharmaceuticals worth $21,834,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Capital World Investors increased its position in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after purchasing an additional 92,101 shares during the last quarter. Vanguard Group Inc. raised its position in Alnylam Pharmaceuticals by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock worth $2,996,296,000 after buying an additional 98,303 shares during the last quarter. Capital Research Global Investors raised its position in Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 39.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after purchasing an additional 1,245,195 shares during the period. Finally, Norges Bank acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $577,941,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock traded up $4.76 during trading hours on Tuesday, hitting $325.28. The stock had a trading volume of 1,268,974 shares, compared to its average volume of 853,616. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $333.70. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. The company has a 50-day moving average of $306.46 and a two-hundred day moving average of $272.05. The company has a market cap of $42.41 billion, a PE ratio of -155.64 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The business's revenue was up 20.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the business's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the sale, the chief executive officer owned 48,948 shares in the company, valued at $14,899,281.72. The trade was a 39.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ALNY has been the topic of several analyst reports. BMO Capital Markets lifted their price target on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a report on Tuesday, June 24th. Stifel Nicolaus boosted their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. UBS Group upped their price target on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Needham & Company LLC upped their price objective on Alnylam Pharmaceuticals from $320.00 to $377.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Finally, Bank of America upped their target price on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a "buy" rating in a report on Friday, July 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-three have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $347.75.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.